ARTICLE | Company News

Halozyme, AbbVie deal

December 2, 2016 12:31 AM UTC

Halozyme said AbbVie discontinued the partners’ first program under a 2015 deal to develop AbbVie compounds using Halozyme’s Enhanze drug delivery platform. The platform uses recombinant human enzyme sperm adhesion molecule 1 (SPAM1; PH20) hyaluronidase to temporarily degrade hyaluronan and improve subcutaneous delivery of injectable biologics (see BioCentury, June 8, 2015). ...